Vericel to Present at the 18th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020

Rhea-AI Summary

Vericel Corporation (NASDAQ: VCEL) announced that Nick Colangelo, its President and CEO, will present at the 18th Annual Morgan Stanley Global Healthcare Conference on September 17, 2020, at 2:45 p.m. ET. The conference will be conducted virtually, and the presentation will be accessible via a live webcast on Vericel's Investor Relations website. Vericel specializes in advanced therapies for sports medicine and severe burn care, with products like MACI® and Epicel®. The company also holds exclusive North American rights to NexoBrid® for burn treatment.

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 18^th Annual Morgan Stanley Global Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, September 17, 2020 at 2:45 p.m. Eastern Time.

A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2020 Vericel Corporation. All rights reserved.

Investor Contacts:
Lee Stern
Solebury Trout
lstern@troutgroup.com
+1 646-378-2922

FAQ

What is the date and time of Vericel Corporation's presentation at the Morgan Stanley Global Healthcare Conference?

Vericel Corporation's presentation will take place on September 17, 2020, at 2:45 p.m. Eastern Time.

Where can I watch the live webcast of Vericel's presentation?

The live webcast of Vericel's presentation will be available on their Investor Relations website at http://investors.vcel.com.

Who is presenting for Vericel Corporation at the Morgan Stanley Conference?

Nick Colangelo, the President and CEO of Vericel Corporation, will be presenting at the conference.

What are the main products offered by Vericel Corporation?

Vericel Corporation offers MACI® and Epicel® as their main products for sports medicine and severe burn care.

What is the significance of NexoBrid® for Vericel Corporation?

NexoBrid® is a registration-stage biological orphan product for the debridement of severe thermal burns, for which Vericel holds exclusive North American rights.